Literature DB >> 9485023

Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line.

Z H Siddik1, B Mims, G Lozano, G Thai.   

Abstract

The p53 tumor suppressor gene is critical in regulating cell proliferation following DNA damage, and disruption of p53 protein function by mutation has been implicated as a factor responsible for resistance of tumor cells to chemotherapeutic agents. Our studies were initiated by asking whether the translational product of the p53 gene is associated with cisplatin resistance in the 2780CP human ovarian tumor model. We have demonstrated by single-strand conformation polymorphism analysis and sequencing that p53 in parental cisplatin-sensitive A2780 cells was wild type. In 2780CP cells, however, a mutation was found in exon 5 at codon 172 (Val to Phe). Interestingly, exposure to X-rays resulted in p53 induction in both A2780 and 2780CP tumor models. The p53 increases by the ionizing radiation were accompanied by concomitant increases in levels of the p53-regulated p21Waf1/Cip1 protein and led to arrest of cells in G1 phase of the cell cycle. A yeast functional assay confirmed that p53 in A2780 was wild type, but, more importantly, it provided evidence that the p53 mutation in 2780CP cells was temperature sensitive and heterozygous. These experiments demonstrate that sensitive and resistant cells have normal p53 functions, despite the presence of p53 mutation in the 2780CP model. In parallel investigations using the Western technique, exposure of A2780 cells to clinically relevant concentrations of cisplatin (1-20 microM) resulted in time- and dose-dependent increases in p53, together with coordinate increases in p21Waf1/Cip1. In contrast, cisplatin did not induce these proteins in 2780CP cells to any significant degree. The results indicate that a defect exists in the signal transduction pathway for p53 induction following cisplatin-induced DNA damage in 2780CP cells, and this may represent a significant mechanism of cisplatin resistance. Furthermore, induction of p53 in 2780CP cells by X-rays, but not cisplatin, strongly suggests that independent pathways are involved in p53 regulation for the two DNA-damaging agents.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9485023

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Restoration of endogenous wild-type p53 activity in a glioblastoma cell line with intrinsic temperature-sensitive p53 induces growth arrest but not apoptosis.

Authors:  J Ikeda; M Tada; N Ishii; H Saya; K Tsuchiya; K Okaichi; K Mishima; Y Sawamura; G Fulci; T J Liu; E G Van Meir
Journal:  Int J Cancer       Date:  2001-10-01       Impact factor: 7.396

2.  Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate.

Authors:  Jonathan F Arambula; Jonathan L Sessler; Zahid H Siddik
Journal:  Bioorg Med Chem Lett       Date:  2011-01-26       Impact factor: 2.823

Review 3.  Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.

Authors:  Michelle Martinez-Rivera; Zahid H Siddik
Journal:  Biochem Pharmacol       Date:  2011-12-26       Impact factor: 5.858

4.  Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.

Authors:  Kalpana Mujoo; Masayuki Watanabe; Junichi Nakamura; Abdul R Khokhar; Zahid H Siddik
Journal:  J Cancer Res Clin Oncol       Date:  2003-09-26       Impact factor: 4.553

5.  Long-term smoking mediated down-regulation of Smad3 induces resistance to carboplatin in non-small cell lung cancer.

Authors:  Debangshu Samanta; Jacob Kaufman; David P Carbone; Pran K Datta
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

6.  Photoinduced reduction of Pt(IV) within an anti-proliferative Pt(IV)-texaphyrin conjugate.

Authors:  Grégory Thiabaud; Jonathan F Arambula; Zahid H Siddik; Jonathan L Sessler
Journal:  Chemistry       Date:  2014-06-24       Impact factor: 5.236

7.  A texaphyrin-oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells.

Authors:  Jonathan F Arambula; Jonathan L Sessler; Zahid H Siddik
Journal:  Medchemcomm       Date:  2012       Impact factor: 3.597

8.  Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner.

Authors:  Tetsuji Kurokawa; Guangan He; Zahid H Siddik
Journal:  Cancer Chemother Pharmacol       Date:  2009-06-16       Impact factor: 3.333

9.  DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells.

Authors:  Sanne R Martens-de Kemp; Simone U Dalm; Fiona M J Wijnolts; Arjen Brink; Richard J Honeywell; Godefridus J Peters; Boudewijn J M Braakhuis; Ruud H Brakenhoff
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

10.  Towards Imaging Pt Chemoresistance Using Gd(III)-Pt(II) Theranostic MR Contrast Agents.

Authors:  Casey J Adams; Thomas J Meade
Journal:  ChemMedChem       Date:  2021-08-06       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.